DXCM at a glance
Dexcom (DXCM, SEC CIK 1093557) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Dexcom (DXCM) reported revenue of $4.7 billion (up 15.6% from FY2024) and net income of $836.3 million. Diluted EPS was $2.09.
- As of September 30, 2026, 38 institutional investment managers tracked by SignalX reported holding Dexcom (DXCM) shares worth $14.8 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Brown Michael Jon on November 16, 2026 of 1,700 shares at $83.46 per share.
- In the last 90 days, DXCM insiders reported 0 open-market purchases ($0) and 9 open-market sales ($2.1M) on Form 4, a net sale of $2.1M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $4.7B
- +15.6% vs prior year
- Insiders · 90 days
- 0 buys · 9 sells
- Net −$2.1M
- 13F holders
- 38 funds
- $14.8B · −1 vs prior quarter
- Latest 8-K
- Oct 29, 2026
- Item 8.01 · Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Design, development, and commercialization of continuous glucose monitoring (CGM) systems for diabetes and metabolic health management
- New product launched: Stelo, first over-the-counter glucose biosensor for prediabetes and Type 2 diabetes adults not using insulin (U.S. launch Aug 2024)
- Strategic shift: Expanded market beyond insulin-using diabetics to prediabetes and broader metabolic health with OTC Stelo product
- Quantitative metric: G7 15 Day system FDA cleared with 15.5-day wear, 8.0% MARD accuracy, coverage by Medicare and Medicaid in majority of U.S. states
- Noteworthy fact: Dexcom ONE+ CGM system received CE Mark approval Nov 2023 and launched in multiple European countries, expanding international presence
Management Discussion & Analysis
- Revenue $4,662M, up 16% YoY from $4,033M driven by 600K-700K net customer additions
- Operating margin 20.0% vs 14.9%, operating income $911.8M up 52% YoY from $600.0M
- Best segment: U.S. distributor revenue $3,195.7M up $371.3M; worst segment: U.S. direct revenue $139.2M up $73.8M (smallest absolute growth)
- Net income $836.3M up 45% YoY with net margin 17.9% vs 14.3%
- Cash from operations supporting R&D ($599.1M), SG&A ($1,291M), no specific buybacks/dividends noted; expectations of adequate liquidity, possible future debt market access for inorganic growth
Risk Factors
- Cybersecurity risk exposure due to integration of cloud-based technology platforms increasing operational costs
- Board Technology Committee delegation for cybersecurity risk oversight with annual compliance reviews to applicable laws and standards
- Key-person dependency on cybersecurity officers with 15-25 years experience and multiple professional certifications managing risk
- Supply chain vulnerability linked to global IT infrastructure managed by CIO with 30 years experience in IT and supply chain
- No specific regulatory, geopolitical, competitive, or financial risk detailed in this section
AI summary of the DXCM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New shareholder-return risk: October 2026 authorization of $1.00 billion 2027 Share Repurchase Program
- Most material update: Repurchases may not enhance share price or earnings per share
- Market risk: Repurchase timing could expose Dexcom to unfavorable market conditions and price volatility
- Financial risk: Share buybacks depend on availability of funds and competing strategic opportunities
Management Discussion & Analysis
- Revenue $1,344.5M, up $135.2M or 11% YoY, driven by disposable sensor volume
- Gross margin 64.3% vs 60.5% YoY, supported by G7 15 Day and manufacturing efficiencies
- Operating income $327.2M, up 35% YoY; operating margin 24.3% vs 20.1%
- Cash $1.82B, down $180.8M from December 31, 2025; nine-month operating cash flow $1.12B
- Share repurchases drove $1,023.8M financing cash use; significant manufacturing capital expenditures expected next year
AI summary of the DXCM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Board authorized up to $1.0 billion in common-stock repurchases through December 31, 2027
- Potential shareholder return and share-count reduction, but no guaranteed repurchase amount
Item EX-99.1: Item EX-99.1
- Q3 revenue $1.344B, up 11% YoY, with U.S. growth 14% versus international growth 5%
- GAAP operating margin 24.3%, up 420 basis points, signaling strong operating leverage
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026 announced
- Investor focus: revenue, profitability, guidance and operating metrics in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- Dexcom announced Mr. Sylvain’s promotion on September 14, 2026
- Promotion details and leadership implications appear in Exhibit 99.1 accompanying the filing
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO Jereme Sylvain promoted to EVP, Chief Operating Officer and CFO, effective September 14, 2026
- Expanded mandate combines financial leadership with operational oversight
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded to 13 directors with immediate appointment of Glenn S. Boehnlein through the 2027 annual meeting
- Independent director adds oversight to Operations & Innovation and Audit committees
Item 7.01: Regulation FD Disclosure
- Dexcom appointed Mr. Boehnlein to its Board, signaling a governance and strategic leadership change
- Appointment details and rationale are contained in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Glenn Boehnlein appointed independent director effective September 10, 2026
- Former Stryker CFO brings 20+ years of MedTech finance and operating experience
AI summaries of DXCM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DXCM
Don't miss the next DXCM filing
- Alerts as it files. A push when DXCM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DXCM, by share count.
- Ask anything. An AI agent that reads every DXCM filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Brown Michael Jon | Sell | Nov 16, 2026 | 1,700 | $83.46 |
| Sylvain Jereme M | F | Nov 8, 2026 | 1,451 | $79.41 |
| Leach Jacob Steven | F | Nov 8, 2026 | 1,451 | $79.41 |
| Brown Michael Jon | F | Nov 8, 2026 | 1,451 | $79.41 |
| Stern Sadie | F | Nov 8, 2026 | 1,451 | $79.41 |
| Ashley Euan A. | G | Oct 30, 2026 | 2,389 | - |
| Stern Sadie | Sell | Oct 27, 2026 | 2,565 | $78.62 |
| Brown Michael Jon | Sell | Oct 15, 2026 | 1,700 | $85.48 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $4.0B | $4.7B |
| Gross Profit | - | $2.4B | $2.8B |
| Operating Income | - | $600.0M | $911.8M |
| Net Income | - | $576.2M | $836.3M |
| Gross Margin | - | 60.5% | 60.1% |
| Op. Margin | - | 14.9% | 19.6% |
| Net Margin | - | 14.3% | 17.9% |
| Balance Sheet | |||
| Total Assets | $6.3B | $6.5B | $6.3B |
| Equity | $2.1B | $2.1B | $2.7B |
| ROE | - | 27.4% | 30.5% |
| Per Share | |||
| EPS | - | $1.42 | $2.09 |
| Cash Flow | |||
| Operating CF | - | $989.5M | $1.4B |
| CapEx | - | $358.8M | $363.5M |
Source: XBRL data in Dexcom (DXCM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate DXCM share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 38 | $14.84B |
| Q2 2026 | 39 | $11.18B |
| Q1 2026 | 36 | $10.28B |
| Q4 2025 | 37 | $11.45B |
| Q3 2025 | 38 | $11.71B |
| Q2 2025 | 36 | $13.89B |
| Q1 2025 | 34 | $8.15B |
| Q4 2024 | 30 | $8.32B |
- Citadel Advisors LLC+2.92M (+241%)
- Franklin Resources+1.52M (+42%)
- Bank of America Corp+1.35M (+43%)
- Renaissance Technologies LLC+715.4K (+44%)
- Invesco Ltd+680.8K (+4%)
- Ameriprise Financial−718.0K (-15%)
- Vanguard Capital Management LLC−505.3K (-2%)
- AQR Capital Management−415.8K (-13%)
- Principal Financial Group−221.3K (-25%)
- Goldman Sachs Group−177.3K (-5%)
- FMR LLC (Fidelity)−1.89M
- AlTi Global, Inc.−16.0K
Source: 13F-HR filings on SEC EDGAR (aggregated from 288 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DXCM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 10, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 8-K | Oct 29, 2026 | - | Analysis | - |
| 10-Q | Oct 29, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 28, 2026 | - | - | - |
| 4 | Oct 19, 2026 | - | - | - |
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 8-K | Sep 10, 2026 | - | Analysis | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 25, 2026 | - | - | - |
| 4 | Aug 24, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
DXCM SEC filings: frequently asked questions
Are DXCM insiders buying or selling?
In the last 90 days, Dexcom (DXCM) officers, directors and 10% owners reported no open-market purchases and 9 open-market sales worth $2.1 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold DXCM stock?
As of September 30, 2026, the largest Dexcom (DXCM) holders among the 13F filers tracked by SignalX were BlackRock ($3.3 billion), Vanguard Capital Management LLC ($2.1 billion), Vanguard Portfolio Management LLC ($1.7 billion), State Street Corp ($1.6 billion), Invesco Ltd ($1.4 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DXCM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Dexcom (DXCM) reported revenue of $4.7 billion (up 15.6% from FY2024) and net income of $836.3 million. Diluted EPS was $2.09. The figures come from the XBRL data in the 10-K.
What are the main risks in DXCM's latest 10-K?
In the 10-K filed February 12, 2026, Dexcom (DXCM) flagged: Cybersecurity risk exposure due to integration of cloud-based technology platforms increasing operational costs. Board Technology Committee delegation for cybersecurity risk oversight with annual compliance reviews to applicable laws and standards. (AI summary of the Risk Factors section.)
What did DXCM report in its latest 8-K?
Dexcom (DXCM) filed an 8-K on October 29, 2026 reporting Item 8.01 (Other Events) and Item 2.02 (Results of Operations and Financial Condition). Board authorized up to $1.0 billion in common-stock repurchases through December 31, 2027.
What are the latest DXCM SEC filings?
Dexcom (DXCM) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on November 18, 2026.
What is DXCM's SEC CIK number?
Dexcom (DXCM)'s SEC Central Index Key (CIK) is 1093557. EDGAR lists every DXCM filing under that number.
Ask anything about DXCM
The research agent reads DXCM's filings, financials, insider trades and 13F holders, then answers with sources.